Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States
- PMID: 35949403
- PMCID: PMC9356679
- DOI: 10.1093/ofid/ofac377
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States
Abstract
A large, ongoing multicountry outbreak of human monkeypox has the potential to cause considerable morbidity and mortality. Therapeutics for the treatment of smallpox, a related Orthopoxvirus, may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan-Orthopoxvirus inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.
Keywords: antiviral; monkeypox; smallpox; tecovirimat.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. All authors: No reported conflicts of interest.
Figures
References
-
- Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005; 41:1742–51. - PubMed
-
- Fleischauer AT, Kile JC, Davidson M, et al. Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 2005; 40:689–94. - PubMed
